The phase 1/2 Bruin study
Prof. Wojciech Jurczak, hematologist at the Maria Sklodowska-Curie National Research Institute Of Oncology in Krakow, Poland discussed the data from the phase 1 / 2 Bruin study evaluating pirtobrutinib in patients with mantle cell lymphoma, pretreated with a covalent BTK-inhibitor. He also highlights potential implications for short-term and long-term clinical practice.
With the educational support of:
